Carvedilol vs. Propranolol in Second Prophylaxis of Variceal Bleeding
Portal Hypertension, Varice Bleed, Cirrhosis, Liver
About this trial
This is an interventional prevention trial for Portal Hypertension
Eligibility Criteria
Inclusion Criteria: Between 18 and 80 years old; With liver cirrhosis diagnosed by previous biopsy or by clinical criteria, and analytical image; At least 5 days after index variceal bleeding; Informed consent. Exclusion Criteria: Refusal to participate in the study; Portal hypertension resulting from other causes than liver cirrhosis; More than 42 days after index variceal bleeding; Bleeding from cardiofundal gastric varices; Portal venous thrombosis >50% of the portal vein trunk; Contraindications to beta-blockers (asthma, chronic obstructive pulmonary disease, atrioventricular block, heart failure, bradycardia with HR ≤40 bpm, arteria hypotension with systolic blood pressure <90 mm Hg, peripheral arterial disease, uncontrolled diabetes); Prior NSBB+EVL combined treatment, TIPS implantation or surgical shunt as secondary prophylaxis of variceal bledding; Chronic kidney disease; Pregnancy or lactation; Neoplastic disease.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Carvedilol
Propranolol
Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 12.5mg/d. Doses are increased 3 days later. Avoid systolic blood pressure <90 mmHg.
Propranolol is started at a dose of 20 mg/d and the dose will be increased by 10 mg twice a day steps every 2-3 days until the target (heart rate: 55~60 bpm) or to a maximum dose of 160 mg/d. Systolic arterial pressure is not less than 90 mm Hg and heart rate is not less than 50 bpm.